; (5) plans for the maintenance and sustainment of federally funded activities conducted at the regional biocontainment laboratories, consistent with the strategy required under section 2312 of the PREVENT Pandemics Act ( Public Law 117–328 ); and (6) activities undertaken by the Secretary to coordinate with applicable agencies to ensure work carried out by such facilities is prioritized and complementary to one another, and avoiding unnecessary duplication. 405. Gene synthesis (a) Guidance Not later than 1 year after the date of enactment of this Act, the Secretary of Health and Human Services (referred to in this section as the Secretary ) shall update the Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA to account for scientific and technological advancements with respect to mitigating risk of unauthorized individuals or individuals with malicious intent from using nucleic acid synthesis technologies to obtain biological agents or toxins of concern. Such guidance shall include recommendations related to— (1) screening for sequences that the Secretary determines may contribute to toxicity, pathogenicity, or virulence; (2) screening and verification of the identity and legitimacy of customers; (3) the identification, evaluation, and use of appropriate software or other tools to enable the screening described in paragraphs (1) and (2); (4) ensuring nucleic acid synthesis activities are carried out in compliance with existing regulations under part 73 of title 42, Code of Federal Regulations, part 331 of title 7, Code of Federal Regulations, part 121 of title 9, Code of Federal Regulations, and part 774 of title 15 Code of Federal Regulations (or successor regulations); (5) implementing appropriate safeguards, which may include the use of such software or other tools, in gene synthesis equipment to facilitate screening of nucleic acid sequences and, as applicable, customers